Venn Life Sciences Holdings PLC Change of Adviser (7348I)
11 Décembre 2015 - 8:00AM
UK Regulatory
TIDMVENN
RNS Number : 7348I
Venn Life Sciences Holdings PLC
11 December 2015
Venn Life Sciences Holdings Plc
("Venn Life Sciences" or the "Company")
Change of Nominated Adviser and Broker
ESM Admission
Venn Life Sciences (AIM: VENN), a growing Contract Research
Organisation (CRO) providing drug development, clinical trial
management and resourcing solutions to pharmaceutical,
biotechnology and medical device clients, announces the appointment
of Davy as the Company's Nominated Adviser and Joint Broker with
effect from 18 January 2016. Hybridan will continue as Joint Broker
to the Company.
The Company will also apply for its shares to be traded on the
Irish Stock Exchange's Enterprises Securities Market (ESM),
alongside its existing AIM listing. Davy will act as ESM Adviser to
the Company from ESM admission, scheduled to occur on 18 January
2016.
Commenting, Venn CEO, Tony Richardson said: "We're very pleased
to be working with the team at Davy and we look forward to the
benefits that the dual-trading facilities of AIM and ESM offers us,
particularly at a time of strong growth and our move into
profitability. We look forward to actively engaging with the wider
audience that the ESM offers us particularly those Eurozone
investors that will be attracted to the addition of a euro
denominated quotation."
Venn Life Sciences Holdings Plc www.vennlifesciences.com
Tony Richardson, Chief Executive Officer Tel: +353 1 549 9341
Jonathan Hartshorn, Chief Financial Officer Tel: +353 1 539 3269
Davy (Nominated Adviser, ESM Adviser and Tel: +353 1 679 6363
Joint Broker(4) )
Fergal Meegan / Matthew DeVere White (Corporate
Finance)
Paul Burke (Corporate Broking)
Hybridan LLP (Joint Broker) Tel: 020 3764 2341
Claire Louise Noyce
Walbrook PR Ltd Tel: 020 7933 8787 or venn@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303
About Venn Life Sciences:
Venn Life Sciences is a Contract Research Organisation providing
drug development, clinical trial management and resourcing
solutions to pharmaceutical, biotechnology and medical device
organisations. With dedicated operations in France, Germany, the
Netherlands, the UK, Ireland and Europe wide representation - Venn
Life Sciences specialises in rapid deployment and management of
multisite projects. Venn Life Sciences also has an innovation
division - Innovenn - focused primarily on breakthrough development
opportunities in Skin Science.
For more information about the Company, please visit:
www.vennlifesciences.com
About Davy:
Established in 1926, the Davy Group, is Ireland's leading
provider of capital markets, financial advisory and wealth &
asset management services. Davy is headquartered in Dublin, with
offices in London, Belfast, Cork and Galway. Employing over 610
people, Davy offers a broad range of services to corporations,
small businesses, private clients and institutional investors, and
organise our activities around four interrelated business areas -
Capital Markets, Corporate Finance, Research, and Wealth &
Asset Management.
As the leading broker in the Irish market, Davy accounted for
over 43% of all dealings in Irish equities on the Irish Stock
Exchange in 2014(1) . Davy is a primary dealer in Irish Government
Bonds and acts as manager on the majority of Irish corporate bond
issues. Davy advises 65% of companies on the Irish Stock
Exchange(2) . On 8 December 2015 Davy Corporate Finance was the
recipient of 'Financial Adviser of the Year - Ireland' Award for
2015 at the annual Mergermarket European M&A Awards. Davy is
Ireland's leading ESM and AIM adviser, representing approximately
74% of companies quoted on the ESM market(2) , and 17 companies
quoted on the AIM market of the London Stock Exchange(3) . Davy is
responsible for over 70% of funds raised on the Irish Stock
Exchange over the past four years(1) and is consistently recognised
by the world's top names in financial services for the quality of
research and service.
(1) Source: Irish Stock Exchange, December 2014
(2) Source: Irish Stock Exchange, December 2015
(3) Source: London Stock Exchange, December 2015
(4) effective from 18 January 2016
For more information about the Company, please visit:
www.davy.ie
This information is provided by RNS
The company news service from the London Stock Exchange
END
APPBBLLFELFBFBD
(END) Dow Jones Newswires
December 11, 2015 02:00 ET (07:00 GMT)
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024